Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
Andrew Berens, an analyst from Leerink Partners, assigned the Buy rating on Cullinan Management (CGEM – Research Report). The associated price ...
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...
GlobalData on MSN3d
Imvax secures $29m to support Phase IIb glioblastoma therapy trial"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...
GlobalData on MSN13d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatmentThe US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
clinicaltrialsarena on MSN5d
Akero’s cirrhosis treatment shows promise in Phase IIb studyAkero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback